Regulus Therapeutics reported $60.98M in Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Alnylam Pharmaceuticals ALNY:US $ 3433.54M 209.76M
AstraZeneca AZN:LN 100273M 5090M
Astrazeneca AZN:US $ 100273M 5090M
Biogen BIIB:US $ 23614.4M 262.9M
Celldex Therapeutics CLDX:US $ 424.04M 20.61M
Gilead Sciences GILD:US $ 63080M 4872M
GlaxoSmithKline GSK:LN 89689M 10586M
Intercept Pharmaceuticals ICPT:US $ 503.36M 23.67M
Intrexon XON:US $ 335.57M 24.29M
Lexicon Pharmaceuticals LXRX:US $ 136.18M 731K
Ligand Pharmaceuticals LGND:US $ 1105.18M 192.41M
Merk MRK:US $ 106668M 974M
Omeros OMER:US $ 369.26M 50M
Regulus Therapeutics RGLS:US $ 60.98M 7.47M
Sangamo Biosciences SGMO:US $ 654.31M 67.61M
Spectrum Pharmaceuticals SPPI:US $ 100.05M 11.49M
Takeda 4502:JP Y 13178018M 479499M
Vital Therapies VTL:US $ 149.92M 10.82M
YTE INCY:US $ 5054.22M 120.87M